OSE Fundamental Analysis - OSE IMMUNO

Fundamental Rating

Overall OSE gets a fundamental rating of 2 out of 10. We evaluated OSE against 83 industry peers in the Biotechnology industry. The financial health of OSE is average, but there are quite some concerns on its profitability. While showing a medium growth rate, OSE is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

OSE had negative earnings in the past year.
OSE had a negative operating cash flow in the past year.
In the past 5 years OSE reported 4 times negative net income.
OSE had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

OSE has a Return On Assets (-33.44%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -68.84%, OSE is doing good in the industry, outperforming 60.24% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-33.44%
ROE	-68.84%
ROIC	N/A

ROA(3y)-5.73%

ROA(5y)-10.16%

ROE(3y)-31.94%

ROE(5y)-31.6%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OSE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

OSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OSE has been increased compared to 1 year ago.
The number of shares outstanding for OSE has been increased compared to 5 years ago.
The debt/assets ratio for OSE has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.13, we must say that OSE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OSE (0.13) is comparable to the rest of the industry.
OSE has a Debt/Equity ratio of 0.64. This is a neutral value indicating OSE is somewhat dependend on debt financing.
OSE's Debt to Equity ratio of 0.64 is in line compared to the rest of the industry. OSE outperforms 50.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.64
Debt/FCF	N/A
Altman-Z	0.13

ROIC/WACCN/A

WACC6.77%

2.3 Liquidity

A Current Ratio of 2.86 indicates that OSE has no problem at all paying its short term obligations.
OSE has a Current ratio (2.86) which is in line with its industry peers.
A Quick Ratio of 2.86 indicates that OSE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.86, OSE is in the better half of the industry, outperforming 61.45% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.86
Quick Ratio	2.86

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

OSE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -191.65%.
Looking at the last year, OSE shows a very negative growth in Revenue. The Revenue has decreased by -97.34% in the last year.
Measured over the past years, OSE shows a very strong growth in Revenue. The Revenue has been growing by 26.31% on average per year.

EPS 1Y (TTM)-191.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-130.08%

Revenue 1Y (TTM)-97.34%

Revenue growth 3Y46.93%

Revenue growth 5Y26.31%

Sales Q2Q%-98.36%

3.2 Future

The Earnings Per Share is expected to decrease by -34.36% on average over the next years. This is quite bad
The Revenue is expected to grow by 15.67% on average over the next years. This is quite good.

EPS Next Y-98.83%

EPS Next 2Y-87.73%

EPS Next 3Y-34.36%

EPS Next 5YN/A

Revenue Next Year-42.08%

Revenue Next 2Y-20.24%

Revenue Next 3Y15.67%

Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSE. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 133.66, which means the current valuation is very expensive for OSE.
Based on the Price/Forward Earnings ratio, OSE is valued a bit cheaper than 73.49% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.12. OSE is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	133.66

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

OSE's earnings are expected to decrease with -34.36% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-87.73%

EPS Next 3Y-34.36%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for OSE!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

OSE IMMUNO

EPA:OSE (1/14/2026, 4:57:59 PM)

4.86

-0.04 (-0.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-15 2025-10-15

Earnings (Next)03-24 2026-03-24/amc

Inst Owners2.8%

Inst Owner ChangeN/A

Ins Owners25.4%

Ins Owner ChangeN/A

Market Cap109.16M

Revenue(TTM)2.22M

Net Income(TTM)-34.84M

Analysts80

Price Target15.61 (221.19%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-7.27%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-93.17%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)9.95%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	133.66
P/S	49.19
P/FCF	N/A
P/OCF	N/A
P/B	2.16
P/tB	14.06
EV/EBITDA	N/A

EPS(TTM)-1.59

EYN/A

EPS(NY)0.04

Fwd EY0.75%

FCF(TTM)-1.66

FCFYN/A

OCF(TTM)-1.66

OCFYN/A

SpS0.1

BVpS2.25

TBVpS0.35

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-33.44%
ROE	-68.84%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-5.73%

ROA(5y)-10.16%

ROE(3y)-31.94%

ROE(5y)-31.6%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score0

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.64
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	2.09%
Cap/Sales	3.06%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.86
Quick Ratio	2.86
Altman-Z	0.13

F-Score0

WACC6.77%

ROIC/WACCN/A

Cap/Depr(3y)5.62%

Cap/Depr(5y)12.68%

Cap/Sales(3y)4%

Cap/Sales(5y)3.16%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-191.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-130.08%

EPS Next Y-98.83%

EPS Next 2Y-87.73%

EPS Next 3Y-34.36%

EPS Next 5YN/A

Revenue 1Y (TTM)-97.34%

Revenue growth 3Y46.93%

Revenue growth 5Y26.31%

Sales Q2Q%-98.36%

Revenue Next Year-42.08%

Revenue Next 2Y-20.24%

Revenue Next 3Y15.67%

Revenue Next 5YN/A

EBIT growth 1Y-165.59%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-72.82%

EBIT Next 3Y-32.92%

EBIT Next 5YN/A

FCF growth 1Y-30.97%

FCF growth 3YN/A

FCF growth 5Y40.61%

OCF growth 1Y-31.28%

OCF growth 3YN/A

OCF growth 5Y39.6%

OSE IMMUNO / OSE.PA FAQ

What is the fundamental rating for OSE stock?

ChartMill assigns a fundamental rating of 2 / 10 to OSE.PA.

What is the valuation status of OSE IMMUNO (OSE.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to OSE IMMUNO (OSE.PA). This can be considered as Overvalued.

What is the profitability of OSE stock?

OSE IMMUNO (OSE.PA) has a profitability rating of 1 / 10.

OSE IMMUNO (OSE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

OSE IMMUNO / OSE.PA FAQ

What is the fundamental rating for OSE stock?

What is the valuation status of OSE IMMUNO (OSE.PA) stock?

What is the profitability of OSE stock?